|
XRN2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.40520000005517E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.69909999999862E-05 |
| Normal-vs-Stage2 |
1.003600E-02 |
| Normal-vs-Stage3 |
1.22690000003978E-06 |
| Normal-vs-Stage4 |
1.25859999999811E-06 |
| Stage1-vs-Stage2 |
6.346200E-01 |
| Stage1-vs-Stage3 |
3.478200E-01 |
| Stage1-vs-Stage4 |
1.293570E-01 |
| Stage2-vs-Stage3 |
3.401800E-01 |
| Stage2-vs-Stage4 |
1.457380E-01 |
| Stage3-vs-Stage4 |
4.220400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.76668999999352E-05 |
| Normal-vs-AfricanAmerican |
9.979500E-03 |
| Normal-vs-Asian |
9.86880000000134E-05 |
| Caucasian-vs-AfricanAmerican |
7.204600E-01 |
| Caucasian-vs-Asian |
5.441600E-01 |
| AfricanAmerican-vs-Asian |
4.701400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.85259999996301E-06 |
| Normal-vs-Female |
1.93581999999859E-05 |
| Male-vs-Female |
2.455800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.161700E-04 |
| Normal-vs-Age(41-60Yrs) |
3.67189999994633E-06 |
| Normal-vs-Age(61-80Yrs) |
4.08009999997017E-06 |
| Normal-vs-Age(81-100Yrs) |
1.254780E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.825600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.591200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.335600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.268600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.922400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.237200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.011440E-01 |
| Classical-VS-Follicular |
5.878600E-03 |
| Classical-VS-Other |
8.112300E-02 |
| Classical-VS-Normal |
2.025500E-04 |
| Tall-VS-Follicular |
7.174800E-01 |
| Tall-VS-Other |
4.112000E-01 |
| Tall-VS-Normal |
1.043540E-04 |
| Follicular-VS-Other |
5.926400E-01 |
| Follicular-VS-Normal |
3.67139999957189E-07 |
| Other-VS-Normal |
2.058200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.55723999999413E-05 |
| Normal-vs-N1 |
4.20899999997726E-06 |
| N0-vs-N1 |
2.750200E-01 |
|
|
